Skip Navigation



JAC Advance Access published online on January 13, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh532
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/2/188    most recent
dkh532v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Muñoz, P.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muñoz, P.
Right arrow Articles by Bouza, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved
Received July 1, 2004
Revised November 9, 2004
Accepted November 10, 2004

Original article

Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital

Patricia Muñoz 1*, Mar Sánchez-Somolinos 1, Luis Alcalá 1, Marta Rodríguez-Créixems 1, Teresa Peláez 1, and Emilio Bouza 1

1 Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario ‘Gregorio Marañón’, Doctor Esquerdo 47, 28006 Madrid, Spain

* To whom correspondence should be addressed.
Patricia Muñoz, E-mail: pmunoz{at}micro.hggm.es


  Abstract

Candida krusei fungaemia is an uncommon entity described in immunocompromised patients previously exposed to azole agents.

From 1988 to 2003, 13 episodes of C. krusei fungaemia (2.3% of all fungaemias) were detected in our institution and compared with 39 Candida albicans controls. Susceptibility testing was carried out with the modified microdilution method according to NCCLS recommendations.

Underlying conditions were: HIV infection (4), haematological malignancies (4), organ transplantation (2), abdominal surgery (2) and lactose intolerance (1). Nine patients (69%) were not neutropenic. In comparison with C. albicans, patients with C. krusei infection had more commonly received antifungal agents (54% versus 15%, P=0.006), had a haematological disease (31% versus 3%, P=0.03), or a transplant (15% versus 3%, P=0.08), were on corticosteroids (47% versus 13%, P=0.01) and were neutropenic (31% versus 0%, P < 0.001). Patients with C. albicans had more surgical interventions (41% versus 15%, P=0.09) and bladder catheters (61% versus 31%, P=0.05). The most common origin for C. albicans was a catheter (41% versus 0%; P=0.006) whereas for C. krusei the most common origin was unknown (69% versus 20%; P=0.001). C. krusei presented more commonly with skin lesions in neutropenic patients (23% versus 5%; P=0.05). Multivariate analysis of these differential characteristics showed that the only factor that independently predicted the presence of C. krusei fungaemia was the administration of antifungal agents before the fungaemia (RR: 6.4; P=0.009; 95%CI 1.6-25.99). Overall mortality of C. krusei fungaemia was 38% (C. albicans 49%). Except for voriconazole (MIC90 0.125 mg/L), azoles and 5-flucytosine had poor activity against C. krusei, whereas amphotericin (MIC90 1 mg/L) and LY-303366 (MIC90 0.06 mg/L) showed good activity.

C. krusei fungaemia incidence remains low despite widespread use of azoles. It may occur outside the setting of cancer patients with previous antifungal use. The presence of skin lesions should be a warning sign.

Keywords: candidosis; candidaemia; transplantation; HIV; neutropenia.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, E. Nagy, S. Dobiasova, M. Rinaldi, R. Barton, A. Veselov, and the Global Antifungal Surveillance Group
Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005
J. Clin. Microbiol., February 1, 2008; 46(2): 515 - 521.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Fleck, A. Dietz, and H. Hof
In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest
J. Antimicrob. Chemother., April 1, 2007; 59(4): 767 - 771.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. D. Jacobsen, N. A. R. Gow, M. C. J. Maiden, D. J. Shaw, and F. C. Odds
Strain Typing and Determination of Population Structure of Candida krusei by Multilocus Sequence Typing
J. Clin. Microbiol., February 1, 2007; 45(2): 317 - 323.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. J. Caston, M. J. Linares, C. Gallego, A. Rivero, P. Font, F. Solis, M. Casal, and J. Torre-Cisneros
Risk Factors for Pulmonary Aspergillus terreus Infection in Patients With Positive Culture for Filamentous Fungi
Chest, January 1, 2007; 131(1): 230 - 236.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.